Expression of the Anti-apoptotic Factors Bcl-2 and Survivin in Canine Vascular Tumours

Journal of Comparative Pathology

Volumn 139, Issue 1, 2008, Pages 1-7

  Murakami, M ^a   Sakai, H ^a   Kodama, A ^a   Mori, T ^a   Maruo, K ^a   Yanai, T ^a   Masegi, T ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

bcl 2; dog; haemangioma; haemangiosarcoma; survivin; tumour

Indexed keywords

MESSENGER RNA; PROTEIN BCL 2; SURVIVIN;

ANGIOSARCOMA; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DOG DISEASE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOMA; HEMANGIOSARCOMA; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; VASCULAR NEOPLASMS;

CANIS FAMILIARIS;

EID: 46749118326     PISSN: 00219975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcpa.2008.02.001     Document Type: Article

References (47)

1. Adams J.M., and Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends in Biochemical Sciences 26 (2001) 61-66
2. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine 3 (1997) 917-921
3. Azad N., Vallyathan V., Wang L., Tantishaiyakul V., Stehlik C., Leonard S.S., and Rojanasakul Y. S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation: a novel antiapoptotic mechanism that suppresses apoptosis. Journal of Biological Chemistry 281 (2006) 34124-34134
4. Bishop E.T., Bell G.T., Bloor S., Broom I.J., Hendry N.F., and Wheatley D.N. An in vitro model of angiogenesis: basic features. Angiogenesis 3 (1999) 335-344
5. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., and Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
6. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer 2 (2002) 647-656
7. Crowston J.G., Chang L.H., Constable P.H., Daniels J.T., Akbar A.N., and Khaw P.T. Apoptosis gene expression and death receptor signaling in mitomycin-C-treated human tenon capsule fibroblasts. Investigative Ophthalmology & Visual Science 43 (2002) 692-699
8. Dickerson E.B., Thomas R., Fosmire S.P., Lamerato-Kozicki A.R., Bianco S.R., Wojcieszyn J.W., Breen M., Helfand S.C., and Modiano J.F. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Veterinary Pathology 42 (2005) 618-632
9. Dickson S.E., Bicknell R., and Fraser H.M. Mid-luteal angiogenesis and function in the primate is dependent on vascular endothelial growth factor. Journal of Endocrinology 168 (2001) 409-416
10. Duval H., Harris M., Li J., Johnson N., and Print C. New insights into the function and regulation of endothelial cell apoptosis. Angiogenesis 6 (2003) 171-183
11. Duval H., Johnson N., Li J., Evans A., Chen S., Licence D., Skepper J., Charnock-Jones D.S., Smith S., and Print C. Vascular development is disrupted by endothelial cell-specific expression of the anti-apoptotic protein Bcl-2. Angiogenesis 10 (2007) 55-68
12. Gamblin R.M., Sagartz J.E., and Couto C.G. Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. American Journal of Veterinary Research 58 (1997) 857-863
13. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., and Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
14. Gerber H.P., Dixit V., and Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. Journal of Biological Chemistry 273 (1998) 13313-13316
15. Hussein M.R., Haemel A.K., and Wood G.S. Apoptosis and melanoma: molecular mechanisms. Journal of Pathology 199 (2003) 275-288
16. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., Isogai E., Ohira M., Hashizume K., Kobayashi H., Kaneko Y., and Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19 (2000) 617-623
17. Kappler M., Kotzsch M., Bartel F., Fussel S., Lautenschlager C., Schmidt U., Wurl P., Bache M., Schmidt H., Taubert H., and Meye A. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clinical Cancer Research 9 (2003) 1098-1104
18. Keshet E., and Ben-Sasson S.A. Anticancer drug targets: approaching angiogenesis. Journal of Clinical Investigation 104 (1999) 1497-1501
19. Kobayashi Y., Yukiue H., Sasaki H., Fukai I., Yokoyama T., Kiriyama M., Yamakawa Y., Maeda M., and Fujii Y. Developmentally regulated expression of survivin in the human thymus. Human Immunology 63 (2002) 101-107
20. Kumaraguruparan R., Prathiba D., and Nagini S. Of humans and canines: immunohistochemical analysis of PCNA, Bcl-2, p53, cytokeratin and ER in mammary tumours. Research in Veterinary Science 81 (2006) 218-224
21. Lamerato-Kozicki A.R., Helm K.M., Jubala C.M., Cutter G.C., and Modiano J.F. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Experimental Hematology 34 (2006) 870-878
22. Lens S.M., Vader G., and Medema R.H. The case for Survivin as mitotic regulator. Current Opinion in Cell Biology 18 (2006) 616-622
23. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., and Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
24. McLaren J., Prentice A., Charnock-Jones D.S., Sharkey A.M., and Smith S.K. Immunolocalization of the apoptosis regulating proteins Bcl-2 and Bax in human endometrium and isolated peritoneal fluid macrophages in endometriosis. Human Reproduction 12 (1997) 146-152
25. Mandriota S.J., and Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. Journal of Cell Science 110 (1997) 2293-2302
26. Mayr B., Zwetkoff S., Schaffner G., and Reifinger M. Tumour suppressor gene p53 mutation in a case of haemangiosarcoma of a dog. Acta Veterinaria Hungarica 50 (2002) 157-160
27. Mesri M., Morales-Ruiz M., Ackermann E.J., Bennett C.F., Pober J.S., Sessa W.C., and Altieri D.C. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. American Journal of Pathology 158 (2001) 1757-1765
28. Modlich U., Kaup F.J., and Augustin H.G. Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Laboratory Investigation 74 (1996) 771-780
29. Nakamura T. Apoptosis and expression of Bax/Bcl-2 proteins in pyogenic granuloma: a comparative study with granulation tissue and capillary hemangioma. Journal of Cutaneous Pathology 27 (2000) 400-405
30. Nasir L., Rutteman G.R., Reid S.W., Schulze C., and Argyle D.J. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas. Cancer Letters 174 (2001) 83-89
31. Nör J.E., Christensen J., Mooney D.J., and Polverini P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. American Journal of Pathology 154 (1999) 375-384
32. Nör J.E., Christensen J., Liu J., Peters M., Mooney D.J., Strieter R.M., and Polverini P.J. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Research 61 (2001) 2183-2188
33. O'Connor D.S., Schechner J.S., Adida C., Mesri M., Rothermel A.L., Li F., Nath A.K., Pober J.S., and Altieri D.C. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. American Journal of Pathology 156 (2000) 393-398
34. Osaka E., Suzuki T., Osaka S., Yoshida Y., Sugita H., Asami S., Tabata K., Hemmi A., Sugitani M., Nemoto N., and Ryu J. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochemica et Cytochemica 39 (2006) 95-100
35. Popovic B., Jekic B., Novakovic I., Lukovic L.J., Tepavcevic Z., Jurisic V., Vukadinovic M., and Milasin J. Bcl-2 expression in oral squamous cell carcinoma. Annals of the New York Academy of Sciences 1095 (2007) 19-25
36. Reed J.C. A day in the life of the Bcl-2 protein: does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation?. Leukemia Research 20 (1996) 109-111
37. Rios-Barrera V.A., Campos-Pena V., Aguilar-Leon D., Lascurain L.R., Meraz-Rios M.A., Moreno J., Figueroa-Granados V., and Hernandez-Pando R. Macrophage and T lymphocyte apoptosis during experimental pulmonary tuberculosis: their relationship to mycobacterial virulence. European Journal of Immunology 36 (2006) 345-353
38. Scase T.J., Edwards D., Miller J., Henley W., Smith K., Blunden A., and Murphy S. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. Journal of Veterinary Internal Medicine 20 (2006) 151-158
39. Schultheiss P.C. A retrospective study of visceral and nonvisceral hemangiosarcoma and hemangiomas in domestic animals. Journal of Veterinary Diagnostic Investigation 16 (2004) 522-526
40. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., Chung C.W., Jung Y.K., and Oh B.H. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40 (2001) 1117-1123
41. Teofoli P., Barduagni S., Ribuffo M., Campanella A., De Pita O., and Puddu P. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. Journal of Dermatological Science 22 (1999) 31-37
42. Trieb K., Lehner R., Stulnig T., Sulzbacher I., and Shroyer K.R. Survivin expression in human osteosarcoma is a marker for survival. European Journal of Surgical Oncology 29 (2003) 379-382
43. Uchide T., Takatsu N., Fujimori Y., Fukushima U., and Itoh H. Expression of survivin mRNA in dog tumors. DNA Sequence 16 (2005) 329-334
44. Yang W.Y., Liu C.H., Chang C.J., Lee C.C., Chang K.J., and Lin C.T. Proliferative activity, apoptosis and expression of oestrogen receptor and Bcl-2 oncoprotein in canine mammary gland tumours. Journal of Comparative Pathology 134 (2006) 70-79
45. Yonemaru K., Sakai H., Murakami M., Yanai T., and Masegi T. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. Veterinary Pathology 43 (2006) 971-980
46. Yonemaru K., Sakai H., Murakami M., Kodama A., Mori T., Yanai T., Maruo K., and Masegi T. The significance of p53 and retinoblastoma pathways in canine hemangiosarcoma. Journal of Veterinary Medical Science 69 (2007) 271-278
47. Zhu C.Q., Shih W., Ling C.H., and Tsao M.S. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. Journal of Clinical Pathology 59 (2006) 790-800